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Interobserver variation in the classification of thymic lesions including biopsies and
resection specimens in an international digital microscopy panel
Aims: Thymic tumours are rare in routine pathology
practice. Although the World Health Organization
(WHO) classification describes a number of well-de-
fined categories, the classification remains challeng-
ing. The aim of this study was to investigate the
reproducibility of the WHO classification among a
large group of international pathologists with exper-
tise in thymic pathology and by using whole slide
imaging to facilitate rapid diagnostic turnover.
Methods and results: Three hundred and five tumours,
consisting of 90 biopsies and 215 resection specimens,
were reviewed with a panel-based virtual microscopy
approach by a group of 13 pathologists with expertise in
thymic tumours over a period of 6 years. The specimens
were classified according to the WHO 2015 classification.
The data were subjected to statistical analysis, and inter-
observer concordance (Fleiss kappa) was calculated. All
cases were diagnosed within a time frame of 2 weeks. The
overall level of agreement was substantial (j = 0.6762),
and differed slightly between resection specimens
(j = 0.7281) and biopsies (j = 0.5955). When analysis
was limited to thymomas only, and they were grouped
according to the European Society for Medical Oncology
Clinical Practice Guidelines into B2, B3 versus A, AB, B1
and B3 versus A, AB, B1, B2, the level of agreement
decreased slightly (j = 0.5506 and j = 0.4929, respec-
tively). Difficulties arose in distinguishing thymoma from
thymic carcinoma. Within the thymoma subgroup, diffi-
culties in distinction were seen within the B group.
Conclusions: Agreement in diagnosing thymic lesions
is substantial when they are assessed by pathologists
with experience of these rare tumours. Digital pathol-
ogy decreases the turnaround time and facilitates
access to what is essentially a multinational resource.
This platform provides a template for dealing with
rare tumours for which expertise is sparse.
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Introduction
Thymic epithelial tumours (TETs) are rare in routine
practice. The estimated incidence of TETs in The
Netherlands is 3.2/100 000.1 These tumours are cat-
egorised according to the 2015 World Health Organi-
zation (WHO) classification into thymoma and
thymic carcinoma. Thymomas are further divided
into five major subtypes (A, AB, B1, B2, and B3) and
rarer other thymomas. Segregation into categories is
based on the relative proportions of the non-neoplas-
tic lymphocytes, the proportions and cytological fea-
tures (degree of atypia) of the neoplastic epithelial
cells, and the resemblance of the tumour to the nor-
mal thymic architecture.2–4 Although the WHO clas-
sification provides a number of well-defined
categories, the diagnosis remains challenging, owing
to both the rarity and the diversity of the tumours.
Several interobserver variability studies have evalu-
ated the reproducibility of the WHO classification,
often in combination with other classification systems,
such as the Bernatz classification5 and the Suster and
Moran6 system.7 The level of interobserver agreement
varies widely within the studies, with j-values ranging
between 0.37 and 0.87. Most difficulties were encoun-
tered in the subclassification of type B thymomas.8–12
In recognition of these classification difficulties, diag-
nostic panels have been set up to improve consistency
and aid the harmonisation of reporting.
In The Netherlands, a thymoma panel was initiated
in 2009. The panel acts as a ‘virtual panel’ of 13
pathologists with a special interest in thymic pathol-
ogy. As this is a virtual panel, its members do not
physically meet but evaluate digitised (scanned) slides
[whole slide imaging (WSI)] by the use of virtual
microscopy. Most panel members are from The
Netherlands, but there are also experts from the USA,
Germany, and the UK. The panel provides subtyping
of the tumour according to the WHO classification
within an anticipated turnaround time of 2 weeks.
To this end, the diagnoses of the panel members are
tabulated and, if at least seven panel members have
formulated an opinion, a consensus diagnosis based
on the majority diagnosis is established and reported
to the submitter. Panel members receive an alert
when a case is finalised, and may review their diag-
nosis. In The Netherlands, submission of cases is vol-
untary, and it is the decision of the primary
diagnosing hospital to request an opinion of the
panel. The panel functions as a Dutch national refer-
ence panel for primary TETs and their differential
diagnoses, and has been used as an example for pan-
els in other areas of diagnostic pathology. Tumours
other than TETs, such as malignant lymphomas,
germ cell tumours, and stromal thymic tumours, are
also included.
The purpose of this study was to investigate the
reproducibility of the WHO classification of TETs
among a large group of international pathologists
with interest and expertise in thymic pathology,
assessed in a large series of successive cases submitted
to the Dutch thymoma panel from 2011 until 2018
by the use of WSI.
Materials and methods
Slides from submitted cases are digitally scanned at a
central facility (Department of Pathology, Erasmus
MC) and made available to panel members for exter-
nal electronic review. The diagnoses are entered in a
dedicated reporting system and summarised within a
set time frame. Both haematoxylin and eosin (H&E)-
stained sections and immunohistochemical stains
from mediastinal masses from 49 hospitals in The
Netherlands and Belgium (including seven university
medical centres) were submitted to the panel between
January 2011 and December 2018. Baseline demo-
graphic and clinical characteristics of the patients
were provided by the submitting pathologist. There
were no specific guidelines provided to the submitting
institutions regarding the number of slides or addi-
tional stains required by the panel.
Tumour slides considered to be diagnostically rele-
vant were scanned with the Hamamatsu NanoZoomer
2.0-HT (Hamamatsu Photonics K.K., Hamamatsu City,
Japan). The scan magnification was set at 9 20
or 9 40 objective, which is equivalent to a resolution
of approximately 9 200 to 9 400 with a normal
microscope. The scans were then placed on a virtual
platform named www.pathpanel.org, where panel
members had access to the virtual slides, which could
be viewed in a suitable viewer such as NDP view 2
(Hamamatsu Photonics K.K.; see examples in Doc S1).
Individual panel members entered their diagnosis in a
categorical system according to WHO subtyping. After
a 2-week evaluation period, a consensus diagnosis was
formulated, which was reported back to the submitting
pathologist. At the start of the panel, a consensus
meeting was organised. In this meeting, potentially
diagnostic criteria and practical issues were discussed,
and adherence to WHO guidelines was strongly
emphasised. For biopsies, a preferential diagnosis of
‘thymoma not otherwise specified (NOS)’ was advo-
cated, and a subtype could be added in the comments.
There was also the possibility of a second-round review
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if additional stains were considered to be essential for a
diagnosis at the time of the first review.
During the period of the study, 13 pathologists were
members of the panel, although the composition of
the panel did change owing to pathologists leaving the
panel and new recruits. Cases were scored according
to the WHO classification by the use of drop-down
lists. Each panel member was thus able to render a
preferred diagnosis individually without knowledge of
the diagnoses of other members. In cases with varied
histology, the proportions of different subtypes could
be added in 10% increments (making a compulsory
100% sum). Alternatively, a ‘non-thymic tumour’ cat-
egory could be used and specified in free text. Free-text
comments could also be made. The criterion for for-
mulating a consensus diagnosis was at least seven
reviewers evaluating one case, and single outlying
diagnoses were excluded from the final evaluation.
The data of all scoring pathologists were subjected to
statistical analysis in Excel 2016 (v16.0) as part of Micro-
soft Office 2016 (Microsoft, Redmond, Washington,
USA), and interobserver concordance (Fleiss kappa) was
calculated.13 (For calculations, see Doc S1.) The j-value
was used to calculate the reliability of agreement
between the different pathologists when assigning cate-
gorical ratings to a number of given cases. A j-value of
≤0.20 was regarded as poor agreement, 0.21–0.40 as
fair agreement, 0.41–0.60 as moderate agreement,
0.61–0.80 as substantial agreement, and 0.81–1.00 as
almost perfect agreement.14 To gain further insights,
clinically relevant diagnostic categories (A, AB, B1 versus
B2, B3, and A, AB, B1, B2 versus B3) were defined, and
j-values between these groups were also calculated.
Within the subgroups, the presence of a type B2 and/or
type B3 minor component was considered in the calcula-
tions. All cases available in the panel were used for statis-
tical analysis if at least seven pathologists participated in
the scoring.
For descriptive purposes, the overall agreement was
divided into five different categories: total agreement
ranging from 95% to 100%, majority ranging from
75% to 94% agreement, consensus ranging from
50% to 74% agreement, trend ranging from 25% to
49% agreement, and lack with <25% agreement.
To illustrate the differences between previous biopsy
and resection specimen, (consensus) diagnoses for both
were listed separately and compared with each other.
Results
Over a period of 8 years, 305 tumours, consisting of
90 biopsies and 215 resection specimens, were
reviewed with a panel-based virtual microscopy
approach. The baseline data of the submitted cases
are summarised in Table 1. The predominant diagno-
sis for submitted cases was thymoma (70%, with type
AB being the most prevalent diagnosis), followed by
thymic carcinoma and benign thymic lesions, such as
thymic cysts (Table 2). In most cases, the panel
Table 1. Baseline demographic and clinical characteristics




Age at diagnosis (years), median (range) 61 (16–88)
Procedure, n (%)
Biopsy 90 (29.5)
Resection specimen 215 (70.5)
Number of pathologists diagnosing a case:
mode (range)
9 (7–12)
Table 2. Distribution of diagnoses in thymoma panel sub-
missions







Other thymoma 3 1
Thymic carcinoma 33 10.8
Carcinoid 1 0.3
Germ cell tumour 2 0.7
Lymphoma 1 0.3
Metastasis 7 2.3
Benign lesion 14 4.6
No consenus diagnosis 8 2.6
MNT-LS, micronodular thymoma with lymphoid stroma; WHO,
World Health Organization.
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members gave no more than two different diagnoses
for a single case (range, 1–7). The modal number of
diagnosing pathologists for a case was nine (range,
7–12). A summary of the level of overall agreement
is given in Table 3. The overall level of agreement
was substantial (j = 0.6762), and differed between
resection specimens (j = 0.7281) and biopsies
(j = 0.5955). When thymomas were subclassified
according to the European Society for Medical Oncol-
ogy (ESMO) clinical practice guidelines for diagnosis,
treatment and follow-up15 into groups including B2,
B3 versus A, AB, B1 and B3 versus A, AB, B1, B2,
the level of agreement decreased from substantial to
moderate (j = 0.5506 and j = 0.4929, respectively)
(Table 4).
The highest level of agreement was reached for
thymoma types A and AB for biopsies and resection
specimens (n = 71; ≥80% per category). Examples
with perfect agreement are shown in Figure 1. Differ-
ences in diagnoses arose in distinguishing thymoma
(n = 8 for B3 and n = 5 for A; ≥10% per category)
from thymic carcinoma, and in distinguishing thymic
carcinoma from metastasis (n = 8; ≥10% per cate-
gory). Within the thymoma subgroups, variation in
subtyping was especially prevalent within the B
group (n = 32 for B1 versus B2 and n = 17 for B2
versus B3; ≥10% per category).
In a further step, the consensus diagnosis of the
biopsies was compared with the consensus diagnosis
of the available matching resection specimen. In
order to prevent bias, panel members were not aware
of cases that had been previously biopsied and had
been submitted to the panel. Of the 90 available biop-
sies, 15 cases could be linked to resection specimens
that were submitted to the panel. There was 73%
agreement between biopsy and resection in a predom-
inant pattern, increasing to 87% (A, AB, B1 versus
B2, B3) and 100% (A, AB, B1, B2 versus B3) for
groupings in the ESMO treatment guidelines
(Table 5).
Discussion
Our study demonstrates substantial interobserver cor-
relation for typing TETs when they were assessed by
an international group of pathologists with experi-
ence in dealing with these rare tumours. However,
because of the rarity of thymic epithelial tumours











62 (20.3) 96 (31.5) 103 (33.8) 43 (14.1) 1 (0.3)
Table 4. Kappa values calculated for all specimens, and separately for biopsies and resection specimens
Diagnoses Percentage agreement (pₐ) Percentage chance agreement (pₑ) j (coefficient) (95% CI)
All diagnoses
Combined 0.8855 0.6466 0.6762 (0.6416–0.7108)
Biopsy 0.7945 0.492 0.5955 (0.5381–0.6530)
Resection 0.9224 0.7147 0.7281 (0.6615–0.7946)
Thymoma split 1
Combined 0.7877 0.5275 0.5506 (0.5134–0.5879)
Biopsy 0.682 0.4919 0.374 (0.2933–0.4547)
Resection 0.824 0.5413 0.6163 (0.5754–0.6573)
Thymoma split 2
Combined 0.7877 0.6951 0.4929 (0.4352–0.5506)
Biopsy 0.7749 0.6578 0.3423 (0.2348–0.4497)
Resection 0.8695 0.7092 0.5512 (0.4940–0.6083)
CI, confidence interval.
Kappa values were calculated for thymoma subgroups, with thymomas divided into two categories with different therapeutic consequences.
Split 1 refers to (A, AB, B1) versus (B2, B3), and split 2 refers to (A, AB, B1, B2) versus (B3).
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 77, 734–741.





Figure 1. Examples of thymomas from the thymoma panel; cases A–D were scored with high consensus rates, and for cases E–H there were
split opinions. A, Encapsulated mediastinal mass scored by seven pathologists, with 100% consensus for type AB thymoma. B, Resected
mediastinal tumour scored by 10 pathologists, with 100% consensus for type A thymoma. C, Resected thymic tumour scored by seven
pathologists, with 99% consensus for type B3 thymoma. (1% type B2). D, Thymic resection unanimously scored by seven pathologists as
thymic carcinoma. E, Biopsy specimen with a thymic epithelial tumour weakly staining for CD5 and strongly staining for p40. CD117 and
terminal deoxynucleotidyl transferase were negative. The specimen was scored by nine pathologists, with an outcome of 55% type B3 thy-
moma and 45% thymic carcinoma. F, Resected encapsulated mediastinal tumour scored by nine pathologists, with an outcome of 74.7%
type B3 thymoma, 22.2% thymic carcinoma, and 3.33% type B2 thymoma. G, Resected anterior mediastinal tumour. The tumour was posi-
tive for p40, cytokeratin (CK) 5, CK19, Pax8, and CD117, and negative for CK7, thyroid transcription factor-1, napsin A, chromogranin,
and synaptophysin. It was scored by nine pathologists, with an outcome of 77.78% thymic carcinoma and 22.22% type A thymoma. H,
Resected multilobular tumour from the anterior mediastinum. The tumour was partly positive for CD5 and CD99, and negative for CD117.
It was scored by 10 pathologists, with an outcome of 58% type B3 thymoma, 23% thymic carcinoma, 10% type AB thymoma, 8% type B2
thymoma, and 1% type A thymoma.
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 77, 734–741.
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and the spectrum of thymoma subtypes, the diagnosis
remains a challenge for many, even experienced,
pathologists, as demonstrated by different interob-
server variability studies. In these studies, the range
of agreement ranged from fair to substantial to
almost perfect, with j-values between 0.34 and 0.87.
This might be explained by the number of evaluating
pathologists, the heterogeneity of the thymic lesions,
the experience of the assessors, and the amount and
variability of cases and additional stains evaluated.8–
10 Evaluation of TETs by a small number of assessors
will usually lead to less interobserver variability, par-
ticularly if the assessors are within a single institute
and frequently discuss cases.11,16,17
To maximise accuracy in diagnosing thymic
tumours, changes were introduced in the 2015 WHO
classification,3 as exemplified in detail in the assess-
ment of the International Thymic Malignancy Inter-
est Group statement on the WHO histological
classification.3 Revision and refinement of histological
and immunohistochemical diagnostic criteria should
lead to more robust and reproducible subtyping of
thymomas and distinction between thymomas and
thymic carcinomas. To these ends, major and minor
diagnostic criteria were introduced, as were recom-
mendations on the use of immunohistochemical
markers for the diagnosis of thymomas with ambigu-
ous histology and thymic carcinomas.
The good level of agreement in our study might be
explained by the high level of expertise of pathologists
from different countries in Europe and the USA, and
the strict adherence to diagnostic criteria, indicating
that the current WHO criteria for classification of
TETs are sufficiently reproducible for diagnostic pur-
poses. However, even with this level of agreement,
cases remain that are challenging to classify. In the
overall group of biopsies and the resection specimens,
the main difficulties arose in distinguishing between
thymic carcinoma and metastasis, between type B3
thymoma and thymic carcinoma and between B3
thymoma and type A thymoma. This might be
explained by the degree of histological overlap.
Although obvious high-grade thymic carcinomas are
readily diagnosed, those cases that show organotypic





Case 1 9 65% MNT-LS (25% AB, 10% A) 10 72.22% MNT-LS (16.66% A, 11.11% AB)
Case 2 7 92.85% B1 (7.15% B2) 7 51.43% B1 (22.86% AB, 25.71% B2)
Case 3 7 47.77% B2 (30% B1, 22.22% AB) 9 100% AB
Case 4 5 80% B1 (20% B2) 9 64% B2 (36% B1)
Case 5 8 84.29% Thymic carcinoma (15.71% B3) 7 88.75% Thymic carcinoma (11.25% B3)
Case 6 8 76.66% B1 (22.22% tNOS, 1.11% NTT) 9 66.25% B1 (33.75% B2)
Case 7 8 78.5% A (21.5% AB) 7 100% A
Case 8 8 66.66% B1 (22.22% NOS, 11.11% B2) 9 36.25% B1 (25% AB, 20% B2, 12.5% other,
6.25% B3)
Case 9 10 56.25% B2 (18.75% B3, 12.5% tNOS, 12.5% AB) 8 88% B2 (12% B1)
Case 10 8 88.88% A (11.11% tNOS) 9 92.5% A (7.5% B3)
Case 11 8 68.18% MNT-LS (22.72% A, 9.09% normal thymus) 11 100% MNT-LS
Case 12 8 68.75% B1 (25% tNOS, 6.25% B2) 8 66.25% B2 (17.5% B1, 12.5% AB, 3.75% B3)
Case 13 10 94.44% A (5.56% AB) 9 100% A
Case 14 8 95% A (5% AB) 10 43.75% A (12.5% AB versus NTT versus other,
10% B3, 7.5% tNOS, 1.25% B2)
Case 15 6 40% MNT-LS versus tNOS (20% AB) 5 65% AB (30% MNT-LS, 5% B1)
MNT-LS, multinodular thymoma with lymphoid stroma; NTT, non-thymic tumour; tNOS, thymoma not otherwise specified.
Consensus diagnoses are given in bold.
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features, such as lobulation and septation, or those
that have limited cytonuclear atypia, overlap consid-
erably with type B3 carcinoma. Furthermore, insuffi-
cient sampling, heterogeneity of the tumour or lack
of additional stains to differentiate between thymoma,
thymic carcinoma and metastasis can make the diag-
nostic process more challenging, as reported by some
pathologists. When thymoma subgroups were evalu-
ated, lower j-values were seen, with most difficulties
being encountered in differentiating between different
type B (B1, B2, and B3) thymomas. These findings
were also reported by Rieker et al.11 Within this sub-
group weighted j-values declined from 0.87 to 0.49.
Kappa values differed between resection specimens
and biopsies, with lower values for biopsies. This
might be explained by the limited amount of available
tissue in a biopsy, and the fact that thymic tumours
can be very heterogeneous. This can make it difficult
to provide a definitive classification on a small core
biopsy, and caution is advocated in this situation.4
However, panel responses vary in these situations,
with some panel members rendering a diagnosis of
thymoma NOS on biopsy specimens, and others sub-
typing if feasible. To evaluate this recommendation,
we linked the biopsies to the available resection speci-
mens. Although the consensus diagnoses of the biop-
sies corresponded with the findings of the resection
specimens in most matched cases (11 of 15 cases;
73%), we noticed differences in subtyping of thy-
moma subgroups. This might be explained by sam-
pling bias, and the presence of different thymic
subtypes within one tumour, and is especially impor-
tant to be aware of in cases in which biopsy subtyp-
ing influences clinical management.
As some therapeutic decisions are based on group-
ings of thymoma subtypes, we performed a subclassifi-
cation of thymomas according to the ESMO clinical
practice guidelines for diagnosis, treatment and follow-
up into groups including (B2, B3) versus (A, AB, B1)
and (B3) versus (A, AB, B1, B2). As stated in the guide-
lines, Masaoka–Koga stage IIA resected thymomas (A,
AB, B1, and B2) will be followed up without further
treatment, whereas postoperative radiotherapy is rec-
ommended for resected type B3 thymomas. In stage
IIB, the recommendation for postoperative radiother-
apy is extended to also include resected type B2 thymo-
mas.15 Therefore, in conjunction with clinical stage,
thymoma subtyping impacts on therapeutic decision-
making. When thymomas were clustered into (B2, B3)
versus (A, AB, B1) and (B3) versus (A, AB, B1, B2), the
level of agreement decreased to moderate (j = 0.5275
and j = 0.4929 respectively), further emphasising the
difficulty in segregating the B subgroups.
A limitation of the study is that, for most cases, the
Dutch thymoma panel received H&E-stained sections
and a small subset of immunohistochemical slides
only, and rarely received tissue blocks or unstained
glass slides that could be used for additional stains.
However, a (consensus) diagnosis was established
with the available material in most cases. Further-
more, in cases deemed to have insufficient material
for a confident diagnosis, the panel could request
additional stains to establish a diagnosis. Therefore,
despite these limitations, the interobserver correlation
was good, but could be enhanced further by expand-
ing and standardising the panel of immunohisto-
chemical stains, especially for subtyping small needle
core biopsies and complex resection specimens.
Future molecular studies might aid in the distinction
between different thymoma subtypes and between thy-
momas and thymic carcinomas. In this respect, alter-
ations of GTF2I, which has a high mutation frequency
in type A and AB thymomas when compared to other
thymoma subtypes and thymic carcinomas, is a good
example.18,19 Other examples are mutations in KIT or
TP53 in thymic carcinomas.20,21
In recent years, the application of digital pathology
using scanned slides (WSI) has increased considerably,
and has been shown to be a reliable alternative to con-
ventional microscopy.22 Development and improve-
ment of scanning technology has resulted in greatly
reduced scanning times, increased resolution, and the
introduction of user-friendly interfaces. A major
advantage of virtual slide technology is easy and con-
venient global sharing of rare tumour cases such as
TETs, as demonstrated by the Dutch thymoma panel,
which, in The Netherlands, was the first of its kind. A
similar study utilising WSI for evaluating TETs was
reported previously by Wang et al.9 The reported over-
all j-value was lower, at 0.39 compared with 0.67 in
our study. This is probably due to differences in the
number and selection of cases, and in the number of
evaluating pathologists. It is of note that in the study of
Wang et al. observer agreement improved in a second
round after discussion of cases, which means that
interpretation of criteria may have originally differed
between pathologists, and that strict adherence is
required for accurate diagnosis of TETs.
Submitting material from rare tumours to an
expert panel can increase the quality of the diagnosis.
With the addition of tissue blocks or unstained sec-
tions, additional ancillary studies can be performed in
the coordinating institution and shared in an online
platform by the use of WSI. This allows experts
around the world to gain access to these rare lesions
and generate the most accurate diagnosis.
© 2020 The Authors. Histopathology published by John Wiley & Sons Ltd, Histopathology, 77, 734–741.
740 J L Wolf et al.
Furthermore, making WSI of all cases with diagnoses
available as an online resource could also provide an
excellent learning tool.
In conclusion, this study shows that, with adher-
ence to the WHO guidelines, substantial agreement
on the classification of TETs is achieved. This study
further indicates that the current WHO criteria allow
good categorisation of TETs. In addition, further con-
firmation of the diagnostic accuracy and rapid turn-
around time of WSI is provided.
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